Latest posts tagged with #FXIa on Bluesky
Bristol Myers Squibb and Johnson & Johnson launched the clinician-focused campaign “Change the Target. Change What’s Possible.” to highlight unmet needs in cardiovascular and thromboembolic care.
#Cardiovascular #Thrombosis #FXIa #ClinicalInnovation
【BMS×J&J、FXIaに着目した循環器・血栓症領域の教育キャンペーン開始】
✔ 「Change the Target. Change What’s Possible.」を開始
✔ 心房細動患者の40％が未治療または治療不十分
✔ FXIa阻害は“出血リスクを高めずに血栓抑制”の可能性
既存治療では「血栓予防」と「出血リスク」のトレードオフが課題。新規標的FXIaがアンメットニーズ解決の鍵となる可能性。
#BMS #JohnsonAndJohnson #FXIa #循環器 #血栓症
9) Another small molecule, #asundexian, was being studied vs #apixaban for #SPAF in #OCEANIC_AF, but that trial was prematurely terminated due to inferior efficacy of the #FXIa inhibitor. See pubmed.ncbi.nlm.nih.gov/39225267/ & discussion by @CMichaelGibson at cardiometabolic-ce.com/antithrombot....
8b) New approaches for #stroke ⬇️ in #AFib have been #MAb against #FXI and small molecule inhibitors of #FXIa. Leading candidate from each of these categories currently in Ph 3 trials: MAb #abelacimab in #LILAC #TIMI-76 & small molecule #milvexian in #LIBREXIA_AF.
8a) Since #FXI was identified as a potential target for #anticoagulation with less bleeding risk (supported by genomic & epidemiologic studies of ppl with inborn FXI deficiency & by animal studies), multiple approaches to inhibition of FXI zymogen or #FXIa activity are being studied.
